Abstract
Introduction: Neuroglial functions may be deteriorated in major depressive disorder (MDD). Objective: To evaluate the markers of glial and neuronal cell turnover and to explore their associations with brain metabolites. Methods: In 10 participants with MDD and 10 healthy controls (HC) we investigated neuronal and glial plasma markers (the neuron-specific enolase, NSE; and S100beta, S100B) and brain metabolites (N-acetyl aspartate, NAA; total choline, Cho; and total creatine, Cr). Blood was collected for NSE and S100B. NAA, Cho, and Cr metabolite levels were measured in the anterior cingulate cortex (ACC) with proton magnetic resonance spectroscopy (1H-MRS) at 3T. Results: NSE and S100B levels were significantly higher in MDD subjects than in HC. The Cr level was significantly higher in MDD subjects than in HC, but the NAA and Cho levels did not differ between groups. NAA/Cr and Cho/Cr ratios were significantly lower in patients with MDD versus HC. S100B was negatively correlated with the Cho levels. Conclusions: These results provide supporting evidence of neuronal and glial distress in MDD. Neuronal viability appears decreased, whereas glial regenerative activity and energy metabolism in the ACC increase in acute major depressive episode. Since low concentrations of S100B have neuroplastic effects, these changes may indicate a possible compensatory mechanism.
References
1.
Halaris
A
, Myint
AM
, Savant
V
, Meresh
E
, Lim
E
, Guillemin
G
, et al Does escitalopram reduce neurotoxicity in major depression?
J Psychiatr Res
. 2015
Jul-Aug
;66-67
:118
–26
.
[PubMed]
0022-39562.
Meier
TB
, Drevets
WC
, Wurfel
BE
, Ford
BN
, Morris
HM
, Victor
TA
, et al Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder
. Brain Behav Immun
. 2016
Mar
;53
:39
–48
.
[PubMed]
0889-15913.
Zavorotnyy
M
, Zöllner
R
, Schulte-Güstenberg
LR
, Wulff
L
, Schöning
S
, Dannlowski
U
, et al Low left amygdala volume is associated with a longer duration of unipolar depression
. J Neural Transm (Vienna)
. 2018
Feb
;125
(2
):229
–38
.
[PubMed]
0300-95644.
Zimmer
DB
, Cornwall
EH
, Landar
A
, Song
W
. The S100 protein family: history, function, and expression
. Brain Res Bull
. 1995
;37
(4
):417
–29
.
[PubMed]
0361-92305.
Pinto
SS
, Gottfried
C
, Mendez
A
, Gonçalves
D
, Karl
J
, Gonçalves
CA
, et al Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology
. FEBS Lett
. 2000
Dec
;486
(3
):203
–7
.
[PubMed]
0014-57936.
Steiner
J
, Bernstein
HG
, Bielau
H
, Berndt
A
, Brisch
R
, Mawrin
C
, et al Evidence for a wide extra-astrocytic distribution of S100B in human brain
. BMC Neurosci
. 2007
Jan
;8
(1
):2
.
[PubMed]
1471-22027.
Schäfer
BW
, Heizmann
CW
. The S100 family of EF-hand calcium-binding proteins: functions and pathology
. Trends Biochem Sci
. 1996
Apr
;21
(4
):134
–40
.
[PubMed]
0968-00048.
Schmitt
KR
, Kern
C
, Lange
PE
, Berger
F
, Abdul-Khaliq
H
, Hendrix
S
. S100B modulates IL-6 release and cytotoxicity from hypothermic brain cells and inhibits hypothermia-induced axonal outgrowth
. Neurosci Res
. 2007
Sep
;59
(1
):68
–73
.
[PubMed]
0168-01029.
Ahmad
O
, Wardlaw
J
, Whiteley
WN
. Correlation of levels of neuronal and glial markers with radiological measures of infarct volume in ischaemic stroke: a systematic review
. Cerebrovasc Dis
. 2012
;33
(1
):47
–54
.
[PubMed]
1015-977010.
Böhmer
AE
, Oses
JP
, Schmidt
AP
, Perón
CS
, Krebs
CL
, Oppitz
PP
, et al Neuron-specific enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury
. Neurosurgery
. 2011
Jun
;68
(6
):1624
–30
.
[PubMed]
0148-396X11.
Arolt
V
, Peters
M
, Erfurth
A
, Wiesmann
M
, Missler
U
, Rudolf
S
, et al S100B and response to treatment in major depression: a pilot study
. Eur Neuropsychopharmacol
. 2003
Aug
;13
(4
):235
–9
.
[PubMed]
0924-977X12.
Grabe
HJ
, Ahrens
N
, Rose
HJ
, Kessler
C
, Freyberger
HJ
. Neurotrophic factor S100 beta in major depression
. Neuropsychobiology
. 2001
;44
(2
):88
–90
.
[PubMed]
0302-282X13.
Hetzel
G
, Moeller
O
, Evers
S
, Erfurth
A
, Ponath
G
, Arolt
V
, et al The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment
. Psychopharmacology (Berl)
. 2005
Mar
;178
(2-3
):161
–6
.
[PubMed]
0033-315814.
Rothermundt
M
, Arolt
V
, Wiesmann
M
, Missler
U
, Peters
M
, Rudolf
S
, et al S-100B is increased in melancholic but not in non-melancholic major depression
. J Affect Disord
. 2001
Sep
;66
(1
):89
–93
.
[PubMed]
0165-032715.
Schroeter
ML
, Abdul-Khaliq
H
, Diefenbacher
A
, Blasig
IE
. S100B is increased in mood disorders and may be reduced by antidepressive treatment
. Neuroreport
. 2002
Sep
;13
(13
):1675
–8
.
[PubMed]
0959-496516.
Schroeter
ML
, Abdul-Khaliq
H
, Krebs
M
, Diefenbacher
A
, Blasig
IE
. Serum markers support disease-specific glial pathology in major depression
. J Affect Disord
. 2008
Dec
;111
(2-3
):271
–80
.
[PubMed]
0165-032717.
Yang
K
, Xie
GR
, Hu
YQ
, Mao
FQ
, Su
LY
. The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression
. J Neural Transm (Vienna)
. 2008
Dec
;115
(12
):1687
–94
.
[PubMed]
0300-956418.
Schmidt
FM
, Mergl
R
, Stach
B
, Jahn
I
, Schönknecht
P
. Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE), but not S100B in major depressive disorder
. World J Biol Psychiatry
. 2015
Feb
;16
(2
):106
–13
.
[PubMed]
1562-297519.
Wiener
CD
, Jansen
K
, Ghisleni
G
, Kaster
MP
, Souza
LD
, Lara
DR
, et al Reduced serum levels of neuron specific enolase (NSE) in drug-naïve subjects with major depression and bipolar disorder
. Neurochem Res
. 2013
Jul
;38
(7
):1394
–8
.
[PubMed]
0364-319020.
Wiener
CD
, Molina
ML
, Passos
M
, Moreira
FP
, Bittencourt
G
, de Mattos Souza
LD
, et al Neuron-specific enolase levels in drug-naïve young adults with major depressive disorder
. Neurosci Lett
. 2016
May
;620
:93
–6
.
[PubMed]
0304-394021.
Yuan
P
, Zhou
R
, Wang
Y
, Li
X
, Li
J
, Chen
G
, et al Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia
. J Affect Disord
. 2010
Jul
;124
(1-2
):164
–9
.
[PubMed]
0165-032722.
Godfrey
KE
, Gardner
AC
, Kwon
S
, Chea
W
, Muthukumaraswamy
SD
. Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: A systematic review and meta-analysis
. J Psychiatr Res
. 2018
Oct
;105
:33
–44
.
[PubMed]
0022-395623.
Luykx
JJ
, Laban
KG
, van den Heuvel
MP
, Boks
MP
, Mandl
RC
, Kahn
RS
, et al Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of (1)H-MRS findings
. Neurosci Biobehav Rev
. 2012
Jan
;36
(1
):198
–205
.
[PubMed]
0149-763424.
Chen
LP
, Dai
HY
, Dai
ZZ
, Xu
CT
, Wu
RH
. Anterior cingulate cortex and cerebellar hemisphere neurometabolite changes in depression treatment: A 1H magnetic resonance spectroscopy study
. Psychiatry Clin Neurosci
. 2014
May
;68
(5
):357
–64
.
[PubMed]
1323-131625.
Iosifescu
DV
, Bolo
NR
, Nierenberg
AA
, Jensen
JE
, Fava
M
, Renshaw
PF
. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder
. Biol Psychiatry
. 2008
Jun
;63
(12
):1127
–34
.
[PubMed]
0006-322326.
Kondo
DG
, Forrest
LN
, Shi
X
, Sung
YH
, Hellem
TL
, Huber
RS
, et al Creatine target engagement with brain bioenergetics: a dose-ranging phosphorus-31 magnetic resonance spectroscopy study of adolescent females with SSRI-resistant depression
. Amino Acids
. 2016
Aug
;48
(8
):1941
–54
.
[PubMed]
0939-445127.
Merkl
A
, Schubert
F
, Quante
A
, Luborzewski
A
, Brakemeier
EL
, Grimm
S
, et al Abnormal cingulate and prefrontal cortical neurochemistry in major depression after electroconvulsive therapy
. Biol Psychiatry
. 2011
Apr
;69
(8
):772
–9
.
[PubMed]
0006-322328.
Olvera
RL
, Caetano
SC
, Stanley
JA
, Chen
HH
, Nicoletti
M
, Hatch
JP
, et al Reduced medial prefrontal N-acetyl-aspartate levels in pediatric major depressive disorder: a multi-voxel in vivo(1)H spectroscopy study
. Psychiatry Res
. 2010
Nov
;184
(2
):71
–6
.
[PubMed]
0165-178129.
Tae
WS
, Kim
SS
, Lee
KU
, Nam
EC
, Koh
SH
. Progressive decrease of N-acetylaspartate to total creatine ratio in the pregenual anterior cingulate cortex in patients with major depressive disorder: longitudinal 1H-MR spectroscopy study
. Acta Radiol
. 2014
Jun
;55
(5
):594
–603
.
[PubMed]
0284-185130.
Henigsberg
N
, Šarac
H
, Radoš
M
, Radoš
M
, Ozretić
D
, Foro
T
, et al Lower choline-containing metabolites/creatine (Cr) rise and failure to sustain NAA/Cr levels in the dorsolateral prefrontal cortex are associated with depressive episode recurrence under maintenance therapy: A proton magnetic resonance spectroscopy retros
. Front Psychiatry
. 2017
Dec
;8
:277
.
[PubMed]
1664-064031.
Zhang
Y
, Han
Y
, Wang
Y
, Zhang
Y
, Li
L
, Jin
E
, et al A MRS study of metabolic alterations in the frontal white matter of major depressive disorder patients with the treatment of SSRIs
. BMC Psychiatry
. 2015
May
;15
(1
):99
.
[PubMed]
1471-244X32.
Rothermundt
M
, Peters
M
, Prehn
JH
, Arolt
V
. S100B in brain damage and neurodegeneration
. Microsc Res Tech
. 2003
Apr
;60
(6
):614
–32
.
[PubMed]
1059-910X33.
First
MB
, Spitzer
RL
, Gibbon
M
, Williams
JB
. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV)
. Washington (DC)
: American Psychiatric Press, Inc.
; 1996
.34.
Çorapçıoğlu
A
, Aydemir
Ö
, Yıldız
M.
[Adaptation to Turkish and reliability of Structured Clinical Interview for DSM-IV, Axis I disorders]. İlaç ve Tedavi Derg. 1999
;12:33-36 [Turkish].35.
Hamilton
M
. A rating scale for depression
. J Neurol Neurosurg Psychiatry
. 1960
Feb
;23
(1
):56
–62
.
[PubMed]
0022-305036.
Akdemir
A
, Örsel
S
, Dağ
İ
. [Turkish reliability and validity of Hamilton Depression Rating Scale] [Turkish]
. Psikiyatri Psikoloji Psikofarmakoloji Derg
. 1996
;4
(4
):251
–9
.1300-738637.
Guy
W
. ECDEU assessment manual for psychopharmacology
. Rockville (MD)
: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs
; 1976
.38.
Folstein
MF
, Folstein
SE
, McHugh
PR
. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician
. J Psychiatr Res
. 1975
Nov
;12
(3
):189
–98
.
[PubMed]
0022-395639.
Gungen
C
, Ertan
T
, Eker
E
, Yasar
R
, Engin
F
. [Reliability and validity of the standardized Mini Mental State Examination in the diagnosis of mild dementia in Turkish population]
. Turk Psikiyatr Derg
. 2002
;13
(4
):273
–81
.1300-216340.
Riley
CA
, Renshaw
PF
. Brain choline in major depression: A review of the literature.
Psychiatry Res Neuroimaging. 2018 Jan;271(November 2017
):142–53.41.
Ruscio
J
. A probability-based measure of effect size: robustness to base rates and other factors
. Psychol Methods
. 2008
Mar
;13
(1
):19
–30
.
[PubMed]
1082-989X42.
Haque
A
, Polcyn
R
, Matzelle
D
, Banik
NL
. New insights into the role of neuron-specific enolase in neuro-inflammation, neurodegeneration, and neuroprotection
. Brain Sci
. 2018
Feb
;8
(2
):33
.
[PubMed]
2076-342543.
Streitbürger
DP
, Arelin
K
, Kratzsch
J
, Thiery
J
, Steiner
J
, Villringer
A
, et al Validating serum S100B and neuron-specific enolase as biomarkers for the human brain - a combined serum, gene expression and MRI study
. PLoS One
. 2012
;7
(8
):e43284
.
[PubMed]
1932-620344.
Ambrée
O
, Bergink
V
, Grosse
L
, Alferink
J
, Drexhage
HA
, Rothermundt
M
, et al S100B serum levels predict treatment response in patients with melancholic depression
. Int J Neuropsychopharmacol
. 2015
Sep
;19
(3
):pyv103
.
[PubMed]
1461-145745.
Maier
H
, Helm
S
, Toto
S
, Moschny
N
, Sperling
W
, Hillemacher
T
, et al S100B, homocysteine, vitamin B12, folic acid, and procalcitonin serum levels in remitters to electroconvulsive therapy: A pilot study
. Dis Markers
. 2018
Jan
;2018
:2358451
.
[PubMed]
0278-024046.
Gerlach
R
, Demel
G
, König
HG
, Gross
U
, Prehn
JH
, Raabe
A
, et al Active secretion of S100B from astrocytes during metabolic stress
. Neuroscience
. 2006
Sep
;141
(4
):1697
–701
.
[PubMed]
0306-452247.
Tramontina
F
, Leite
MC
, Gonçalves
D
, Tramontina
AC
, Souza
DF
, Frizzo
JK
, et al High glutamate decreases S100B secretion by a mechanism dependent on the glutamate transporter
. Neurochem Res
. 2006
Jun
;31
(6
):815
–20
.
[PubMed]
0364-319048.
Marchi
N
, Rasmussen
P
, Kapural
M
, Fazio
V
, Kight
K
, Mayberg
MR
, et al Peripheral markers of brain damage and blood-brain barrier dysfunction
. Restor Neurol Neurosci
. 2003
;21
(3-4
):109
–21
.
[PubMed]
0922-602849.
Jang
BS
, Kim
H
, Lim
SW
, Jang
KW
, Kim
DK
. Serum S100B levels and major depressive disorder: its characteristics and role in antidepressant response
. Psychiatry Investig
. 2008
Sep
;5
(3
):193
–8
.
[PubMed]
1738-368450.
Dietrich
DE
, Hauser
U
, Peters
M
, Zhang
Y
, Wiesmann
M
, Hasselmann
M
, et al Target evaluation processing and serum levels of nerve tissue protein S100B in patients with remitted major depression
. Neurosci Lett
. 2004
Jan
;354
(1
):69
–73
.
[PubMed]
0304-394051.
Forester
BP
, Harper
DG
, Jensen
JE
, Ravichandran
C
, Jordan
B
, Renshaw
PF
, et al 31Phosphorus magnetic resonance spectroscopy study of tissue specific changes in high energy phosphates before and after sertraline treatment of geriatric depression
. Int J Geriatr Psychiatry
. 2009
Aug
;24
(8
):788
–97
.
[PubMed]
0885-623052.
Harper
DG
, Jensen
JE
, Ravichandran
C
, Perlis
RH
, Fava
M
, Renshaw
PF
, et al Tissue type-specific bioenergetic abnormalities in adults with major depression
. Neuropsychopharmacology
. 2017
Mar
;42
(4
):876
–85
.
[PubMed]
0893-133X53.
Yang
XR
, Langevin
LM
, Jaworska
N
, Kirton
A
, Lebel
RM
, Harris
AD
, et al Proton spectroscopy study of the dorsolateral prefrontal cortex in youth with familial depression
. Psychiatry Clin Neurosci
. 2016
Jul
;70
(7
):269
–77
.
[PubMed]
1323-131654.
Yoon
S
, Kim
JE
, Hwang
J
, Kim
TS
, Kang
HJ
, Namgung
E
, et al Effects of creatine monohydrate augmentation on brain metabolic and network outcome measures in women with major depressive disorder
. Biol Psychiatry
. 2016
Sep
;80
(6
):439
–47
.
[PubMed]
0006-322355.
Dilsaver
SC
. Cholinergic mechanisms in depression
. Brain Res
. 1986
Sep
;396
(3
):285
–316
.
[PubMed]
0006-899356.
Janowsky
DS
, Risch
SC
, Gillin
JC
. Adrenergic-cholinergic balance and the treatment of affective disorders
. Prog Neuropsychopharmacol Biol Psychiatry
. 1983
;7
(2-3
):297
–307
.
[PubMed]
0278-584657.
Saricicek
A
, Esterlis
I
, Maloney
KH
, Mineur
YS
, Ruf
BM
, Muralidharan
A
, et al Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder
. Am J Psychiatry
. 2012
Aug
;169
(8
):851
–9
.
[PubMed]
0002-953X58.
Mader
I
, Rauer
S
, Gall
P
, Klose
U
. (1)H MR spectroscopy of inflammation, infection and ischemia of the brain
. Eur J Radiol
. 2008
Aug
;67
(2
):250
–7
.
[PubMed]
0720-048X59.
Sheng
JG
, Mrak
RE
, Griffin
WS
. Glial-neuronal interactions in Alzheimer disease: progressive association of IL-1alpha+ microglia and S100beta+ astrocytes with neurofibrillary tangle stages
. J Neuropathol Exp Neurol
. 1997
Mar
;56
(3
):285
–90
.
[PubMed]
0022-306960.
Steiner
J
, Schiltz
K
, Walter
M
, Wunderlich
MT
, Keilhoff
G
, Brisch
R
, et al S100B serum levels are closely correlated with body mass index: an important caveat in neuropsychiatric research
. Psychoneuroendocrinology
. 2010
Feb
;35
(2
):321
–4
.
[PubMed]
0306-4530© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
